Alliance for Cancer Gene Therapy Inc
Acgt supports high-risk, high-reward scientific research to develop cancer therapeutics that use the body's own cells and genes as a living medicine. By accelerating this research, acgt is helping to advance therapies that are significantly more effective and less toxic than current cancer treatments such as chemotherapy and radiation.
Alliance for Cancer Gene Therapy Inc at a glance
In short: Alliance for Cancer Gene Therapy Inc gave $4.3M across 5 grants in 2025 (avg $866K), mostly in Pennsylvania. Source: 2025 IRS Form 990.
- Annual giving (2025)
- $4,328,750
- +322.1% vs 2024
- Grants made (2025)
- 5
- +0.0% vs 2024
- Average grant
- $865,750
- +322.1% vs 2024
- Median grant
- $930,284
- Total assets
- $15,733,028
- +4.6% vs 2024
- Primary geography
- Pennsylvania (55% of itemized 2025 grant dollars)
- Latest 990 filing
- Form 990, 2025 View filing
Data from IRS Form 990, 2025; updated September 2026.
How to apply to Alliance for Cancer Gene Therapy Inc
Open Grants
2 open opportunities from Alliance for Cancer Gene Therapy Inc
2026 ACGT Investigator Award in Cell and Gene Therapy for Solid Tumor Cancers
Alliance for Cancer Gene Therapy Inc
Amount
$250,000 - $500,000
Deadline
Deadline not published
Biotech Funding Program
Alliance for Cancer Gene Therapy Inc
Amount
Varies
Deadline
Deadline not published
Who Alliance for Cancer Gene Therapy Inc funds
How this funder distributes its grants
Top Recipients
Top 5 recipients in 2025
The largest 2025 recipient was The Children's Hospital of Philadelphia ($1.5M). Together the top 5 received $4.3M.
Grant Size Distribution
30 grants across all recorded years
The most common grant size was under $50K: 16 grants of 30 (53%).
Geographic Focus
Where this funder awards grants
Grant Distribution by State
Share of 2025 grant dollars across all 5 itemized grants.
Cities
How Alliance for Cancer Gene Therapy Inc gives
- Giving grew 250% from 2022 to 2025. Method
From the foundation's IRS Form 990 filings. Methodology.
Giving History
Giving Over Time
Total grant dollars and number of grants per year
From 2021 to 2025, annual grant giving ranged from $1.0M (2024) to $4.3M (2025). In 2025 it made 5 grants totaling $4.3M.
Grants by year
Grant recipients and amounts by year
| Recipient | Purpose | Amount |
|---|---|---|
| The Children's Hospital of Philadelphia Philadelphia, PA | Cancer Research | $1,462,868 |
| St Jude Children's Research Hospital Memphis, TN | Cancer Research | $1,446,554 |
| University of Pennsylvania Office of Research Services Philadelphia, PA | Cancer Research | $930,284 |
| Fred Hutchinson Cancer Center Seattle, WA | Cancer Research | $482,561 |
| University of Texas MD Anderson Cancer Center Houston, TX | Cancer Research | $6,483 |
Ready to take the next step with Alliance for Cancer Gene Therapy Inc?
Financial History
Multi-year comparison from IRS filings
| Filing year | Total Assets | Revenue | Expenses | Grants paid | Grants | Net Investment Income |
|---|---|---|---|---|---|---|
| 2025 | $15,733,028 | $3,103,520 | $5,355,546 | $4,328,750 | 5 | $917,192 |
| 2024 | $15,042,870 | $9,059,178 | $1,966,204 | $1,025,423 | 5 | $294,442 |
| 2023 | $7,929,383 | $3,231,770 | $2,498,579 | $1,735,341 | 6 | $435,133 |
| 2022 | $7,018,537 | $3,295,905 | $1,804,221 | $1,237,350 | 6 | $607,713 |
| 2021 | $6,851,434 | $1,716,695 | $2,586,563 | $1,759,533 | 8 | $206,963 |
About Alliance for Cancer Gene Therapy Inc
Based on IRS filings
Alliance for Cancer Gene Therapy Inc is a public charity, based in Stamford, CT. IRS filing data is available from 2021 through 2025. As of 2025, the organization holds $15.7M in total assets. In 2025, it awarded 5 grants totaling $4.3M. Net investment income was $917K.
Focus Areas
Leadership & Key People
Officers and directors from IRS filings
Alliance for Cancer Gene Therapy Inc is led by Kevin Honeycutt, CEO & President since 2025 (on filings since 2021); 2 of 21 officers listed in 2025 are compensated.
Officers on the 2025 filing
Kevin Honeycutt
CEO & President
President & CEO → President, CEO & Director, 2023
President, CEO & Director → CEO & President, 2025
On filings since 2021
40 hrs/week
No compensation reported
Barbara Netter
Director & Honorary Chairman
Honorary Chairman → Director & Honorary Chairman, 2025
On filings since 2021
6 hrs/week
No compensation reported
Alexandra Landes
Director
On filings since 2021
1 hr/week
No compensation reported
Chau Q. Khuong
Director
On filings since 2021
1 hr/week
No compensation reported
Daniel Englander
Director
On filings since 2021
1 hr/week
No compensation reported
John C. Sites Jr.
Director
On filings since 2021
1 hr/week
No compensation reported
John L. Lahey PhD
Director
On filings since 2021
1 hr/week
No compensation reported
Klaus R. Veitinger MD PhD
Director
On filings since 2021
1 hr/week
No compensation reported
Martin E. Winter
Director
On filings since 2021
1 hr/week
No compensation reported
Michael Gregory
Director
On filings since 2021
1 hr/week
No compensation reported
Peter A. Glicklich Esq.
Director
On filings since 2021
1 hr/week
No compensation reported
Theresa Burgess PhD
Director
On filings since 2021
1 hr/week
No compensation reported
Chen Schor
Director
On filings since 2022
1 hr/week
No compensation reported
Gbola Amusa
Director
On filings since 2022
1 hr/week
No compensation reported
Maria Fardis PhD
Director
On filings since 2023
1 hr/week
No compensation reported
Bruce L. Levine PhD
Director
New on the 2025 filing
1 hr/week
No compensation reported
Marc Engelsgjerd MD
Director
New on the 2025 filing
1 hr/week
No compensation reported
Barbara Lavery
Chief Program Officer
On filings since 2021
40 hrs/week
$213K (2021) → $264K (2025)
Keri Eisenberg
Chief Philanthropy Officer
On filings since 2024
40 hrs/week
$194K (2024) → $215K (2025)
Christine Herman
Vice President & Treasurer
On filings since 2021
2 hrs/week
No compensation reported
H. William Smith
Vice President, Legal & Secretary
On filings since 2021
2 hrs/week
No compensation reported
Former officers (6)
- Former: Gbola Amusamd (2023–2024) — Director
- Former: Andrew Alisberg (2021–2022) — Director
- Former: David M. Darst Jr. (2021–2022) — Director
- Former: Martha Zoubek (2021–2022) — Director
- Former: Tracy B. Holton (2021–2022) — Director
- Former: David Englanber (2022) — Director
Data from IRS Form 990 filings, 2021–2025. "On filings since" is the earliest filing we hold that lists the person; hours are average hours per week as reported.
Compensation Overview
From 2025 IRS filing
The highest reported compensation on the 2025 filing was $264K, to Barbara Lavery (Chief Program Officer). 2 officers or directors reported compensation on that filing.
Frequently asked questions about Alliance for Cancer Gene Therapy Inc
How much does Alliance for Cancer Gene Therapy Inc give each year?
Alliance for Cancer Gene Therapy Inc gave $4.3M across 5 grants in 2025, according to its 2025 IRS Form 990. In 2024 it gave $1.0M across 5 grants.
What is Alliance for Cancer Gene Therapy Inc's typical grant size?
Alliance for Cancer Gene Therapy Inc's median grant in 2025 was $930,284, and its average grant was $865,750, across 5 grants on its 2025 IRS Form 990.
Where does Alliance for Cancer Gene Therapy Inc give grants?
Alliance for Cancer Gene Therapy Inc gives mostly in Pennsylvania: 55% of the grant dollars itemized on its 2025 IRS Form 990 went to recipients there. The next largest states were Tennessee (33%) and Washington (11%). The most frequent recipient cities were Philadelphia, PA (2 grants).
Does Alliance for Cancer Gene Therapy Inc give general operating support?
Not in 2025: none of the 5 grants with a stated purpose on Alliance for Cancer Gene Therapy Inc's 2025 IRS Form 990 were described as general or operating support. Recurring purposes include "Cancer Research" (5 grants).
Who are Alliance for Cancer Gene Therapy Inc's largest grantees?
Alliance for Cancer Gene Therapy Inc's largest 2025 grantees include The Children's Hospital of Philadelphia ($1,462,868), St Jude Children's Research Hospital ($1,446,554) and University of Pennsylvania Office of Research Services ($930,284), according to its 2025 IRS Form 990. Together they received 89% of its itemized 2025 grant dollars.
How large is Alliance for Cancer Gene Therapy Inc?
Alliance for Cancer Gene Therapy Inc reported $15.7M in total assets on its 2025 IRS Form 990. Its revenue that year was $3.1M.
What is Alliance for Cancer Gene Therapy Inc's EIN?
Alliance for Cancer Gene Therapy Inc's EIN (Employer Identification Number) is 06-1619523. IRS Form 990 filing data is available on this page for 2021–2025.
Data last updated September 2026. Sourced from IRS Form 990 filings.
Data update history
(6)
When this profile's IRS filing data changed on Grantable
- Updated Form 990 for fiscal year 2021 (received by the IRS March 3, 2022)
- Updated Form 990 for fiscal year 2022 (received by the IRS March 7, 2023)
- Updated Form 990 for fiscal year 2023 (received by the IRS January 22, 2024)
- Updated Form 990 for fiscal year 2024 (received by the IRS February 25, 2025)
- Updated Form 990 for fiscal year 2025 (received by the IRS September 11, 2025)
- IRS filings on file for fiscal years 2021–2025
Live grants for the work Alliance for Cancer Gene Therapy Inc funds
Philanthropy, Voluntarism & Grantmaking Open opportunities, soonest deadline first.
Explore Open Grants
Browse active grant opportunities in Alliance for Cancer Gene Therapy Inc's focus areas in our free grants database
Similar Funders
Funders that support many of the same organizations
Conquer Cancer Foundation of the American Society of Clinical Oncology
Alexandria, VA
Conquer Cancer funds cancer research, professional education, and quality-care initiatives, with awards to universities, hospitals, and cancer centers in the U.S. and through international programs. Its 2024 grants ranged from $50,000 to $7.68 million, with a median of $100,000; the profile does not state whether it accepts unsolicited requests.
Assets
$120.7M
Grants
39
Total Given
$17.4M
The Mark Foundation for Cancer Research (US) Ltd
New York, NY
The Mark Foundation for Cancer Research funds basic, translational, and clinical cancer research, including collaborative projects and early-stage drug discovery, at institutions in the U.S. and internationally. Its 2024 grants ranged from $11,250 to $2.75 million, with a median of $500,000; ASPIRE individual applications may be considered by invitation, and no general unsolicited-request policy is stated.
Assets
$105.5M
Grants
29
Total Given
$19.5M
The V Foundation
Cary, NC
The V Foundation funds high-risk, high-reward research on all types of cancer through researchers at cancer centers and other exceptional institutions in the United States and selected Canadian centers. Its grants vary by program; 2025 awards ranged from $84,000 to $3.2 million, with a median of $800,000. It does not accept unsolicited requests; selected institutions are invited to apply.
Assets
$145.9M
Grants
53
Total Given
$56.7M
Benaroya Research Institute at Virginia
Seattle, WA
Benaroya Research Institute funds research on immune-system health and disease, including autoimmunity, allergies, asthma, and cancer, primarily through grants to research and medical institutions. Its 2025 grants had a median of about $105,000, with awards ranging from $5,419 to $10.7 million, and went to organizations across the U.S., with the largest share of funding going to California. The profile does not state whether it accepts unsolicited requests.
Assets
$95.5M
Grants
66
Total Given
$27.5M
The Broad Institute Inc
Cambridge, MA
The Broad Institute funds biomedical research, especially work on disease causes, treatments, cancer, and research technologies, primarily through grants to universities, hospitals, and research centers. In 2025, grants ranged from $8,419 to $15.75 million, with a median of about $301,000; most funding went to Massachusetts organizations. The profile does not state whether it accepts unsolicited requests.
Assets
$3.5B
Grants
77
Total Given
$86.0M
Blood Cancer United Inc
Washington, DC
Blood Cancer United funds blood cancer research, including basic, translational, and clinical studies, along with patient and family support, quality-of-life work, and advocacy. Its 2025 grants ranged from $37,500 to $5,197,687, with a median of $370,000; funding supports work in the U.S. and internationally. The profile does not state whether it accepts unsolicited requests.
Assets
$532.2M
Grants
67
Total Given
$47.7M
More similar funders
More Funders in Connecticut
The filing figures on this page are open data under CC BY 4.0. About GrantGraph Open
Figures come from Alliance for Cancer Gene Therapy Inc's IRS filings (methodology). AI-written summaries, news items and logos are not covered by the open licence. Spot an error? Email hello@grantable.co.
Alliance for Cancer Gene Therapy Inc down — hundreds of funders to go?